ReviewFrontiers in cellular and infection microbiology2022
Determination of phage susceptibility as a clinical diagnostic tool: A routine perspective.
Review in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 55 citations in OpenAlex.
- Farm-adapted multicomponent bacteriophage preparation for environmental biocontrol in commercial dairy cattle housing: A One Health approach.Veterinary world · 2026Article
- Receptor Structure Shapes Host Range but Incompletely Predicts High Activity inAntibiotics (Basel, Switzerland) · 2026Article
- Approaching the post-antibiotic era: phage therapy current practices and future horizons.mBio · 2026Review
- Phage therapy: from basic biology to clinical application.Nature reviews. Microbiology · 2026Review
- Phage as a prospective arsenal against superbugs.Molecular biology reports · 2026Review
- Pharmacology of Bacteriophage Therapy in Children: A Re-Emerging Paradigm in Antibacterial Therapy.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Rapid and quantitative measurement of bacteriophage infectivity via fully automated droplet digital PCR.Nature communications · 2026Article
- Bacteriophage Heteroresistance as a Cause of Treatment Failure in Urinary Tract Infections.bioRxiv : the preprint server for biology · 2026Article
- Comparison and correlation of in vitro and in vivo approaches for determining Pseudomonas aeruginosa bacteriophages activity.BMC microbiology · 2026Article
- Precision of a phage susceptibility spot assay assessed with 154 clinicalMicrobiology spectrum · 2026Article
- Pharmacodynamic individualization of phage therapy against a KPC-5-producingJAC-antimicrobial resistance · 2026Article
- Article
- Towards accurate artificial intelligence models for strain-level phage-host prediction.Briefings in bioinformatics · 2026Article
- Novel bacteriophages effectively target multidrug-resistant clinical isolates of Klebsiella pneumoniae.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Genomic and virulence characterization of OXA-48-producingFrontiers in microbiology · 2026Article
- Genomic and functional characterization of novel therapeutic lytic bacteriophages targeting multidrug-resistantFrontiers in microbiology · 2026Article
- A bacteriophage genus infects carbapenem resistantiScience · 2025Article
- Biological characterization and genome analysis of Pseudomonas phage ZAM-Pa99 as a promising anti-biofilm agent.Molecular biology reports · 2025Article
- Optical Density-Based Methods in Phage Biology: Titering, Lysis Timing, Host Range, and Phage-Resistance Evolution.Viruses · 2025Review
- A Phylogenetic Host-Range Index Reveals Ecological Constraints in Phage Specialisation and Virulence.Molecular ecology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the global burden of disease caused by multidrug resistant bacteria is a major source of concern, credible clinical alternatives to antibiotic therapy, such as personalized phage therapy, are actively explored. Although phage therapy has been used for more than a century, the issue of an easy to implement diagnostic tool for determining phage susceptibility that meets current routine clinical needs is still open. In this Review, we summarize the existing methods used for determining phage activity on bacteria, including the three reference methods: the spot test, the double agar overlay plaque assay, and the Appelmans method. The first two methods rely on the principle of challenging the overnight growth of a lawn of bacteria in an agar matrix to a known relative phage to bacteria concentration and represent good screening tools to determine if the tested phage can be used for a "passive" and or "active" treatment. Beside these methods, several techniques, based on "real-time" growth kinetics assays (GKA) have been developed or are under development. They all monitor the growth of clinical isolates in the presence of phages, but use various detection methods, from classical optical density to more sophisticated techniques such as computer-assisted imagery, flow-cytometry, quantitative real-time polymerase chain reaction (qPCR) or metabolic indicators. Practical considerations as well as information provided about phage activity are reviewed for each technique. Finally, we also discuss the analytical and interpretative requirements for the implementation of a phage susceptibility testing tool in routine clinical microbiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.